Nebivolol in the treatment of cardiac failure: A double-blind controlled clinical trial

Journal of Cardiac Failure

Volumn 3, Issue 4, 1997, Pages 271-276

  Uhlir, O ^a,c   Dvorak, I ^b   Gregor, P ^c   Malek, I ^a,c   Spinarova, L ^b   Vojacek, J ^c   Van Nueten, L ^d  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Beta blockade; Cardiac insufficiency; Drug treatment; Nitric oxide

Indexed keywords

BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; NEBIVOLOL; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BENZOPYRANS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 0031298914     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(97)90026-9     Document Type: Article

References (16)

1. Ertl G, Neubauer S, Gaudron P: Beta-blockers in cardiac failure. Edit Cardiol 1995;1:3-15
2. Panfilov V, Wahlqvist I, Olsson G: Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drugs Ther 1995;9:273-287
3. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218
4. Cleland JGF, Swedberg K: Carvedilol for heart failure, with care. Lancet 1996;347:1199-1201
5. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group: The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
6. Pfeffer MA, Stevenson LW: β-adrenergic blockers and survival in heart failure. N Engl J Med 1996;334:1396-1397
7. Fitzgerald JD: First nebivolol investigators' meeting. Drug Invest 1991;3(suppl. 1):1-203
8. Cockroft JR, Chowienczyk PJ, Brett SE, Chen CPL-H, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM: Nebivolol vasodilates human forearm vasculature: Evidence for a L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;35:1067-1071
9. Bowman AJ, Chen CPL, Ford GA: Nitric oxide-mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204
10. Rousseau MF, Chapelle F, Van Eyll C, Stoleru L, Hager D, Van Nueten L, Pouleur H: Medium-term effects of β-blockade on left ventricular dynamics: a double-blind placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996;2:15-23
11. Wisenbaugh T, Katz I, Davis J, Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardioyopathy. J Am Coll Cardiol 1993;21:1094-1100
12. Van Rooy P, Van Nueten L, De Crée J: Nebivolol: blood pressure reduction in relation to beta-blockade in healthy volunteers. Drug Invest 1991;3(suppl. 1):174-175
13. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS: A dose response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-144
14. Gao Y, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Card Pharmacol 1991;17:964-969
15. Habib F, Dutka D, Crossman D, Oakley CM, Cleland JGF: Enhanced nitric oxide production in heart failure: another failed counter-regulatory mechanism? Lancet 1994;344:371-373
16. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS: Increased nitric oxide production in heart failure. Lancet 1994;344:373-374